Adding the new drug nesiritide (Natrecor) to other therapies soon after patients are admitted for acute decompensated heart failure (HF) saves health care resources in critical care units and may improve overall care and stability, researchers said December 12th here at the clinical meeting of the American Society of Health-System Pharmacists.
They conducted their study in part because nesiritide is the first new therapy for HF in more than a decade, said Dr. Daniel E. Hilleman, of Creighton University Medical Center in Omaha, Nebraska, United States.
Twenty patients, admitted to the hospital with HF, were treated with nesiritide within 36 hours. An equal number of patients with HF who were closely matched -based on age, gender, race HF etiology and other factors -did not receive the drug.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!